1. 6‐Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy.
- Author
-
Yu, Natalie, Lee, Tanya, Tassone, Daniel, Vogrin, Sara, Phan, Steven, Wu, Damien M., Zhang, Jason, Wang, Luke, Tjahyadi, Jason, Dutt, Krishneel, Liou, Hana, Basnayake, Chamara, Wright, Emily, Niewiadomski, Ola, Lust, Mark, Schulberg, Julien, Kamm, Michael A., Connell, William, Thompson, Alexander J., and Hilmi, Ida
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *COMBINATION drug therapy , *ANTI-inflammatory agents , *DRUG toxicity , *CROSS-sectional method , *RECEIVER operating characteristic curves , *ERYTHROCYTES , *DATA analysis , *CROHN'S disease , *STEROIDAL anti-inflammatory agents , *MULTIPLE regression analysis , *TERTIARY care , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *MANN Whitney U Test , *ULCERATIVE colitis , *INFLAMMATORY bowel diseases , *NUCLEOTIDES , *ADALIMUMAB , *PURINES , *DRUG efficacy , *RESEARCH , *MEDICAL records , *ACQUISITION of data , *STATISTICS , *GASTROINTESTINAL agents , *INFLIXIMAB , *DRUG dosage , *DRUG administration - Abstract
Background: Thiopurine co‐therapy with anti‐tumour necrosis factor‐alpha (anti‐TNFα) agents is associated with higher anti‐TNFα drug levels and reduced immunogenicity in inflammatory bowel disease (IBD). Aims: We aimed to evaluate the association between 6‐thioguanine nucleotide (6‐TGN) and anti‐TNFα levels and the optimal 6‐TGN threshold level associated with higher anti‐TNFα levels in combination therapy. Methods: We performed a retrospective cross‐sectional multicentre study of patients with IBD on combination anti‐TNFα and thiopurine maintenance therapy between January 2015 and August 2021. Primary outcomes were infliximab and adalimumab levels. Secondary outcomes were antibodies to infliximab (ATI) or adalimumab (ATA). Univariable and multivariable linear regression were performed to identify variables associated with anti‐TNFα levels. Receiver operator characteristic curves were used to define the optimal 6‐TGN cut‐off levels associated with therapeutic anti‐TNFα levels. Results: The study included 743 paired 6‐TGN and anti‐TNFα levels (640 infliximab and 103 adalimumab). 6‐TGN levels were associated with infliximab levels, but not adalimumab levels, on univariable and multivariable regression. The optimal 6‐TGN cut‐off associated with therapeutic infliximab levels (≥5 mcg/mL) was 261 pmol/8 × 108 red blood cell (RBC) (area under the curve (AUC) = 0.57) for standard infliximab dosing and 227.5 pmol/8 × 108 RBC (AUC = 0.58) for escalated dosing. For therapeutic adalimumab levels (≥7.5 mcg/mL), the 6‐TGN cut‐off was 218.5 pmol/8 × 108 RBC (AUC = 0.59) for standard adalimumab dosing and 237.5 pmol/8 × 108 RBC (AUC = 0.63) for escalated dosing. Conclusion: 6‐TGN levels were weakly associated with infliximab but not adalimumab levels in combination therapy. 6‐TGN levels in the lower end of the therapeutic range (230–260 pmol/8 × 108 RBC) may be adequate to maintain higher infliximab levels, particularly with escalated infliximab dosing. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF